Literature DB >> 10147676

Dry powder inhalers: advantages and limitations.

G K Crompton1.   

Abstract

New inhalers have been developed because of difficulty of using the conventional metered dose inhaler (MDI) and because of the impending ban on CFC's. Dry powder inhalers (DPI's) in general are easier to use than the MDI and cause fewer irritant effects. Unlike the MDI few patients develop a poor inhalation technique with continued use of DPI's. Comparisons of multidose DPI's have shown that they achieve a similar degree of bronchodilatation to the MDI. Comparisons of the Diskhaler and Turbuhaler have shown little difference in therapeutic efficacy, but most indicate patient preference for the Turbuhaler. The inspiratory flow necessary to achieve a therapeutic effect is critical with DPI's. The majority of patients with severe acute asthma can achieve a peak inspiratory flow sufficient to inhale a bronchodilator from a Turbuhaler. DPI's cannot be used with spacers; this may be a disadvantage in patients who inhale large doses of steroids.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 10147676     DOI: 10.1089/jam.1991.4.151

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  12 in total

1.  Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides.

Authors:  Alamdar Hussain; Quamrul H Majumder; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2006-12-07       Impact factor: 4.200

2.  Inhalable lactose-based dry powder formulations of low molecular weight heparin.

Authors:  Shuhua Bai; Vivek Gupta; Fakhrul Ahsan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

3.  Characterization of spray dried powders with nucleic acid-containing PEI nanoparticles.

Authors:  Tobias W M Keil; Daniel P Feldmann; Gabriella Costabile; Qian Zhong; Sandro da Rocha; Olivia M Merkel
Journal:  Eur J Pharm Biopharm       Date:  2019-08-21       Impact factor: 5.571

Review 4.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

5.  Impact of crystalline and amorphous matrices on successful spray drying of siRNA polyplexes for inhalation of nano-in-microparticles.

Authors:  Tobias Wm Keil; Christoph Zimmermann; Domizia Baldassi; Friederike Adams; Wolfgang Friess; Aditi Mehta; Olivia M Merkel
Journal:  Adv Ther (Weinh)       Date:  2021-05-07

6.  Influence of fluoxetine on olanzapine pharmacokinetics.

Authors:  Denis Gossen; Jean-Marie de Suray; Francois Vandenhende; Claude Onkelinx; Diamon Gangji
Journal:  AAPS PharmSci       Date:  2002

7.  Biopharmaceutical Evaluation of Novel Cyclosporine A Nano-matrix Particles for Inhalation.

Authors:  Hideyuki Sato; Hiroki Suzuki; Keisuke Yakushiji; Jennifer Wong; Yoshiki Seto; Robert K Prud'homme; Hak-Kim Chan; Satomi Onoue
Journal:  Pharm Res       Date:  2016-05-25       Impact factor: 4.200

8.  Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model.

Authors:  Yu Lin; Diana Quan; Rachel Yoon Kyung Chang; Michael Y T Chow; Yuncheng Wang; Mengyu Li; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2020-11-27       Impact factor: 5.571

Review 9.  Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes.

Authors:  Mark L Levy; Will Carroll; José L Izquierdo Alonso; Claus Keller; Federico Lavorini; Lauri Lehtimäki
Journal:  Adv Ther       Date:  2019-09-02       Impact factor: 3.845

10.  Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.

Authors:  Maria F Acosta; Michael D Abrahamson; David Encinas-Basurto; Jeffrey R Fineman; Stephen M Black; Heidi M Mansour
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.